This latest article on BioPharmaLife discusses how even though clinical trials in the US are going through a rough patch the Indian pharma outsourced industry is expected to thrive due to the economic crisis.
With many companies pulling back on investments, drug-makers are turning to India for cheaper resources for manufacturing and research. By the year 2011, the US is expected to have outsourced 65% of all its clinical trials to India.
No comments:
Post a Comment